Cargando…
Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges
SIMPLE SUMMARY: Efficacy of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration....
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303745/ https://www.ncbi.nlm.nih.gov/pubmed/34298644 http://dx.doi.org/10.3390/cancers13143430 |
_version_ | 1783727162308689920 |
---|---|
author | Helderman, Roxan F. C. P. A. Löke, Daan R. Tanis, Pieter J. Tuynman, Jurriaan B. Ceelen, Wim de Hingh, Ignace H. van der Speeten, Kurt Franken, Nicolaas A. P. Oei, Arlene L. Kok, H. Petra Crezee, Johannes |
author_facet | Helderman, Roxan F. C. P. A. Löke, Daan R. Tanis, Pieter J. Tuynman, Jurriaan B. Ceelen, Wim de Hingh, Ignace H. van der Speeten, Kurt Franken, Nicolaas A. P. Oei, Arlene L. Kok, H. Petra Crezee, Johannes |
author_sort | Helderman, Roxan F. C. P. A. |
collection | PubMed |
description | SIMPLE SUMMARY: Efficacy of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assists in designing potentially more effective treatment protocols and clinical trials. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature. In total, 60 articles were included in this study. The selected articles were screened on the HIPEC parameters. Recommendations are provided and possible pitfalls are discussed on the choice of type of animal and tumor model per stratified parameters and study goal. The guidelines presented in this paper can improve the clinical relevance and impact of future in vivo HIPEC experiments. ABSTRACT: Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for patients with peritoneal metastasis (PM) of various origins which aims for cure in combination with cytoreductive surgery (CRS). Efficacy of CRS-HIPEC depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assist in designing potentially more effective treatment protocols and clinical trials. The different methodologies for peritoneal disease and HIPEC are variable. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature. In this review, recommendations are provided and possible pitfalls are discussed on the choice of type of animal and tumor model per stratified parameters and study goal. The guidelines presented in this paper can improve the clinical relevance and impact of future in vivo HIPEC experiments. |
format | Online Article Text |
id | pubmed-8303745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83037452021-07-25 Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges Helderman, Roxan F. C. P. A. Löke, Daan R. Tanis, Pieter J. Tuynman, Jurriaan B. Ceelen, Wim de Hingh, Ignace H. van der Speeten, Kurt Franken, Nicolaas A. P. Oei, Arlene L. Kok, H. Petra Crezee, Johannes Cancers (Basel) Review SIMPLE SUMMARY: Efficacy of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assists in designing potentially more effective treatment protocols and clinical trials. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature. In total, 60 articles were included in this study. The selected articles were screened on the HIPEC parameters. Recommendations are provided and possible pitfalls are discussed on the choice of type of animal and tumor model per stratified parameters and study goal. The guidelines presented in this paper can improve the clinical relevance and impact of future in vivo HIPEC experiments. ABSTRACT: Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for patients with peritoneal metastasis (PM) of various origins which aims for cure in combination with cytoreductive surgery (CRS). Efficacy of CRS-HIPEC depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assist in designing potentially more effective treatment protocols and clinical trials. The different methodologies for peritoneal disease and HIPEC are variable. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature. In this review, recommendations are provided and possible pitfalls are discussed on the choice of type of animal and tumor model per stratified parameters and study goal. The guidelines presented in this paper can improve the clinical relevance and impact of future in vivo HIPEC experiments. MDPI 2021-07-08 /pmc/articles/PMC8303745/ /pubmed/34298644 http://dx.doi.org/10.3390/cancers13143430 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Helderman, Roxan F. C. P. A. Löke, Daan R. Tanis, Pieter J. Tuynman, Jurriaan B. Ceelen, Wim de Hingh, Ignace H. van der Speeten, Kurt Franken, Nicolaas A. P. Oei, Arlene L. Kok, H. Petra Crezee, Johannes Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges |
title | Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges |
title_full | Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges |
title_fullStr | Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges |
title_full_unstemmed | Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges |
title_short | Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges |
title_sort | preclinical in vivo-models to investigate hipec; current methodologies and challenges |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303745/ https://www.ncbi.nlm.nih.gov/pubmed/34298644 http://dx.doi.org/10.3390/cancers13143430 |
work_keys_str_mv | AT heldermanroxanfcpa preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges AT lokedaanr preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges AT tanispieterj preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges AT tuynmanjurriaanb preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges AT ceelenwim preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges AT dehinghignaceh preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges AT vanderspeetenkurt preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges AT frankennicolaasap preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges AT oeiarlenel preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges AT kokhpetra preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges AT crezeejohannes preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges |